Motion Analysis Corp.

Mr. Henry who brings over 30 years of health care and management experience is the chairman and CEO of Reimbursement Specialists. He founded his venture capital business, Henry Venture Fund, in 1982. In his venture fund activities, Mr. Henry has invested $30 million in 15 different health care companies and returned $164 million to investors over twenty years for an annual IRR of 51.7%. Mr. Henry had operating roles at eight of these companies which he seed-financed. The capitalized market value of these 15 companies is $1.6 billion in current dollars. Mr. Henry is also Chairman of MSO Medical (MSO), which is a management service organization committed to setting up bariatric surgery centers at acute care and surgical hospitals. MSO recently set up its first Institute for Bariatric Medicine at the Detroit Medical Center. Reimbursement Specialists performs billing and reimbursement services for MSO Medical. Mr. Henry is also currently Chairman and founder of Synergy Pharmaceuticals, a drug development company founded by Henry Venture II which has developed three different technology platforms that are responsible for four potential drugs targeted at myeloma, colon cancer, ulcerative colitis, hepatitis C and hepatitis B. Synergy is currently in a Phase I / II clinical trial for hepatitis C, and is about to enter a Phase II trial for myeloma. Synergy has granted licenses to United Therapeutics for Synergy intellectual property in a $25 million collaboration which, if successful, is forecast to generate royalty revenue of $1.4 billion to Synergy by 2010,according to KPMG, at the rate of approximately$150 million per year. Recently, Mr. Henry was Vice Chairman of IVAC Medical Systems, Inc. Henry Venture II and River Medical acquired IVAC from Eli Lilly Corporation for$200 million in a leveraged transaction in December1994. As Vice Chairman of IVAC, Mr. Henry was responsible for the operating performance of IVAC, and prepared, implemented and managed the 1995 and 1996IVAC business plans, which produced $42 million EBITDA in 1995 and $58.5 million of EBITDA in 1996.IVAC reported $4.5 million of EBITDA when it was acquired December 31, 1994. IVAC was sold for $400million cash in November 1996, which resulted in a500% return on equity over two years after leverage. Previously, Mr. Henry was Director, Chief Financial Officer, Chairman, Executive Committee of IMED responsible for the operating performance of IMED from1978 to 1982 at which time it reported annual revenues of $125 million and $48 million of pretax income. IMED designed, manufactured and sold the first volumetric infusion pump in the world. IMED was purchased by Warner Lambert in August 1982 for $465 million cash payable at closing. In the early 1970's he founded and managed Henry &Associates, a Wall Street institutional research and M&A firm for 10 years, which concentrated on healthcare and technology sectors of the market. Formerly, he was responsible for commercial and industrial loans at Citibank for 42 New York City branch banks, having previous Citibank National Division direct lending experience in the health care, electronic and aerospace industries. Mr. Henry is currently Chairman of Henry Venture II Limited, a venture capital firm focused on the health care industry, and a director of Motion Analysis Corporation. He is also Adjunct Professor of Finance at J.L. Kellogg Graduate School of Business, Northwestern University and a director of the Kellogg Center for Biotechnology. He is a member of Kellogg Alumni Advisory Board and the Advisory Board of the Kellogg Heizer Center for Entrepreneurial Studies at Northwestern University, the Western Association of Venture Capitalists, New York Society of Securities Analysts, American Society of Civil Engineers and Association of Investment Management Research. Mr. Henry holds a BS in Civil Engineering from Bradley University and an MBA in Finance and Marketing from J.L. Kellogg Graduate School of Business at...